Serious Cardiac Arrhythmias with Medicines:
A Population Perspective
Wellcome Collection Conference Centre,
18 September 2008
Confirmed speakers include:
John Camm
British Heart Foundation Professor of Clinical Cardiology,
Elijah Behr
Senior Lecturer and Honorary Consultant Electrophysiologist,
Andrew Grace
Consultant Cardiologist,
Rashmi Shah
Pharmaceutical Consultant and
Jamie Geier
Associate Director, Epidemiology,
Clinical Research Fellow,
Director,
Including the launch of
The
Arrhythmia Studies in Populations
Serious Cardiac Arrhythmias with Medicines Symposium
This symposium will provide a broad overview of the regulatory, pharmacological and clinical concerns surrounding serious cardiac arrhythmias and medicines. Safety issues regarding potential arrhythmias (prolongation of cardiac repolarisation (prolongation of the QT interval), ventricular fibrillation, Torsades de Pointes) are important considerations for regulators and the pharmaceutical industry in the evaluation of new and established products. It has been acknowledged that there is a requirement to widen research in this area by large population study methodologies. We propose that many important questions can be answered in the post-marketing stage by collaboration of cardiologists and drug safety experts to enrich our knowledge in this important and expanding field.
Launch of
At this meeting we will be launching our new venture of national population studies of cardiac arrhythmias, capitalising on our already established infrastructure and arrhythmia network. We can offer the opportunity to utilise our unique experience in electrophysiology and drug safety to undertake bespoke safety studies at a population level as an important part of post-marketing Risk Management Plans.
Programme & Registration
View or download the Programme
To register, please complete the Registration Form and either fax, email or post it to us.
In the event of unforeseen circumstances, DSRU Education & Research Ltd reserves the right to alter the programme, speakers or venue. DSRU Education & Research Limited (Reg. No. 4213474) is a company limited by guarantee where all profits go to the Drug Safety Research Trust, a registered medical charity (No. 327206).